0001209191-20-027143.txt : 20200505 0001209191-20-027143.hdr.sgml : 20200505 20200505163504 ACCESSION NUMBER: 0001209191-20-027143 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200501 FILED AS OF DATE: 20200505 DATE AS OF CHANGE: 20200505 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sacks Natalie CENTRAL INDEX KEY: 0001683811 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38800 FILM NUMBER: 20849450 MAIL ADDRESS: STREET 1: C/O ADURO BIOTECH, INC. STREET 2: 740 HEINZ AVENUE CITY: BERKELEY STATE: CA ZIP: 94710 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Harpoon Therapeutics, Inc. CENTRAL INDEX KEY: 0001708493 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473458693 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 131 OYSTER POINT BOULEVARD STREET 2: SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-443-7400 MAIL ADDRESS: STREET 1: 131 OYSTER POINT BOULEVARD STREET 2: SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-05-01 0 0001708493 Harpoon Therapeutics, Inc. HARP 0001683811 Sacks Natalie C/O HARPOON THERAPEUTICS, INC. 131 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Medical Officer Common Stock 2020-05-01 4 M 0 5826 2.12 A 51580 D Common Stock 2020-05-01 4 S 0 5826 12.0668 D 45754 D Employee Stock Option (right to buy) 2.12 2020-05-01 4 M 0 5826 0.00 D 2028-10-17 Common Stock 5826 168926 D The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Represents the weighted average sales price per share. The shares sold at prices ranging from $11.81 to $12.31 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. The stock option vested and became exercisable as to 25% of the shares subject to the option on October 1, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. /s/ Natalie Sacks by Christopher Whitmore, Attorney-in-Fact 2020-05-05